MedTrace Logo

Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma

NCT07030400 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-04-01

No results posted yet for this study

Summary

The study aims to improve our understanding of how quality of life, fatigue, and symptoms change over 2 years when participants are treated for chronic lymphocytic leukemia or small lymphocytic lymphoma. We will compare two types of treatment to help future patients with chronic lymphocytic leukemia or small lymphocytic lymphoma know what to anticipate.

Conditions

  • Small Lymphocytic Lymphoma (SLL)
  • Chronic Lymphocytic Leukemia (CLL)

Interventions

DRUG

Bruton's tyrosine kinase inhibitor

BTKi

DRUG

B-Cell Lymphoma 2 Protein Inhibitor

BCL2i

Sponsors & Collaborators

Principal Investigators

  • Sara Tinsley-Vance, PhD, APRN, AOCN · Moffitt Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-17
Primary Completion
2028-06-30
Completion
2028-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07030400 on ClinicalTrials.gov